cemiplimab
sanofi,regeneron
['nsclc', 'empower,lung,3', 'lung', 'sclc', 'empower-lung 1', 'cemiplimab', 'lcsm,(-blcsm)']
#esmo22 | #empower-lung 1 trial: 3 years survival outcome and continued cemiplimab beyond progression with addition of chemo in #nsclc. #lcsm 
Latest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it